<DOC>
	<DOCNO>NCT00831636</DOCNO>
	<brief_summary>This non randomise , open label , dose finding , efficacy safety study , enrol patient advanced ( stage III IV ) ovarian cancer It conduct two successive phase . Phase II two-step design</brief_summary>
	<brief_title>A Phase I/II Study CP-4055 Patients With Platinum Resistant Ovarian Cancer</brief_title>
	<detailed_description>Phase I - Three eligible patient enrol dose level ( DL ) , accord standard dose escalation decision rule - Patients receive CP-4055 increase DLs maximum tolerate dose recommend dose ( RD ) establish Phase II - Step 1 ( The patient inclusion may stop step ) : - Patients enrol RD maximum 16 evaluable patient DL - Step 2 : - Depending response rate step 1 , 26 patient include treated step 2</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Histologically cytologically document advanced epithelial ovarian cancer measurable CT and/or MRI Received prior chemotherapy regimen ( ) ovarian cancer , least one platinum base therapy ( PBT ) Evidence platinum resistant refractory disease ECOG Performance Status 0 1 Life expectancy &gt; 3 month Signed informed consent ( IC ) Women childbearing potential must negative serum urine pregnancy test . Nursing patient exclude . Women childbearing potential must become pregnant participate study Adequate haematological biological function Patients mixed mullerian tumour ( MMT ) ( carcinosarcoma ) Known brain metastases Another know active cancer within last 5 year Radiotherapy 30 % bone marrow Participation another therapeutic clinical study within 30 day enrolment clinical study Concomitant treatment nonpermitted medication A history allergic reaction sensitivity attribute compound similar biological composition CP4055 , i.e. , araC and/or egg Any serious concomitant systemic disorder incompatible clinical study Any significant CNS psychiatric disorder ( ) would hamper patient 's compliance Pregnancy breastfeed Known positive status HIV and/or hepatitis B C Drug and/or alcohol abuse Any reason , investigator 's opinion , patient participate</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>CP-4055</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>advanced ovarian cancer</keyword>
	<keyword>stage III IV ovarian cancer</keyword>
	<keyword>advanced epithelian ovarian cancer</keyword>
</DOC>